Zafgen Inc (NASDAQ:ZFGN) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $17.33.
A number of research analysts have recently commented on ZFGN shares. BidaskClub cut shares of Zafgen from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 5th. ValuEngine raised shares of Zafgen from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Cowen reissued a “hold” rating on shares of Zafgen in a research report on Monday, June 25th. Zacks Investment Research raised shares of Zafgen from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. Finally, Wedbush assumed coverage on shares of Zafgen in a research report on Thursday, August 2nd. They set an “outperform” rating and a $14.00 target price on the stock.
Shares of NASDAQ ZFGN traded down $0.25 during trading on Thursday, reaching $10.25. 98,500 shares of the stock were exchanged, compared to its average volume of 273,528. Zafgen has a twelve month low of $3.37 and a twelve month high of $12.35. The company has a current ratio of 8.42, a quick ratio of 8.42 and a debt-to-equity ratio of 0.36. The stock has a market cap of $430.25 million, a P/E ratio of -5.51 and a beta of -0.64.
Zafgen (NASDAQ:ZFGN) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.02. On average, research analysts expect that Zafgen will post -2.05 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Acuta Capital Partners LLC acquired a new stake in Zafgen in the second quarter valued at $2,558,000. AlpInvest Partners B.V. acquired a new stake in Zafgen in the second quarter valued at $1,436,000. Private Advisor Group LLC acquired a new stake in Zafgen in the second quarter valued at $153,000. Point72 Asset Management L.P. acquired a new stake in Zafgen in the second quarter valued at $5,013,000. Finally, Rhumbline Advisers acquired a new stake in Zafgen in the second quarter valued at $214,000. 72.58% of the stock is currently owned by hedge funds and other institutional investors.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Read More: S&P 500 Index
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.